CHICAGO--(BUSINESS WIRE)--Advanced Life Sciences Holdings, Inc. (NASDAQ: ADLS) today announced that its novel respiratory antibiotic, Cethromycin, was shown to be effective in preventing inhalation anthrax infection. This conclusion was reached from a primate study where a 30-day course of oral Cethromycin was 100% protective against a lethal dose of inhaled anthrax as compared to the standard of care, Cipro(r) (ciprofloxacin), which demonstrated 90% protection.
